Skip to main content
OpenTrials
Completed

NCT Number: NCT00702494

Phase I Study on Monoclonal Antibody TB-403 Directed Against PlGF in Patients With Solid Tumours

TB-403 is a monoclonal antibody directed against Placental Growth Factor (PlGF). The antibody binds to PlGF and inhibits the binding to it's receptor, VEGF-1. By preventing this binding, growth of tumor vessels are inhibited and tumor growth prevented.

In this study we are investigating the tolerability and safety of TB-403 in patients with solid tumors who receives multiple intravenous doses of TB-403.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Solid Tumors

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Onkologisk Klinik 5072 Finsencentret Rigshospitalet, Copenhagen, Denmark

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Confirmed malignity
  • Measurable disease
  • Performance status 1 or less (ECOG)

Exclusion criteria

  • Acute illness or infection
  • Concurrent second malignancy

Treatment and study plan

TB-403

Biological

Multiple IV

Primary outcomes

  1. Safety and tolerability of an anti-PlGF antibody

    Time frame: 85 days

Secondary outcomes

  1. Determine multiple dose IV pharmacokinetics

    Time frame: 85 days

Sponsors and collaborators

Lead sponsor

BioInvent International AB

Industry

Collaborators

  • Oxurion

Registry information

Official study title

An Open, Phase I, Dose Escalation Study of the Monoclonal Antibody TB-403 Directed Against PlGF, Given as Multiple IV-doses to Patients With Solid Tumors.

Important dates

Study start
2008
Primary completion
2009
Study completion
2009
First posted
Jun 20, 2008
Registry last updated
Mar 16, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.